أعرض في EDS

Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy

التفاصيل البيبلوغرافية
العنوان: Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy
المؤلفون: Karl D. Lewis, Céleste Lebbé, Kent C. Shih, Patrick Terheyden, Janice M. Mehnert, Michele Milella, Omid Hamid, Marcis Bajars, Christine Hicking, Paul Nghiem, Gerald P. Linette, Andrew S. Brohl, Shailender Bhatia, Meliessa Hennessy, Isaac Brownell, Sandra P. D'Angelo
المصدر: Journal of Clinical Oncology. 36:9507-9507
بيانات النشر: American Society of Clinical Oncology (ASCO), 2018.
سنة النشر: 2018
مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Poor prognosis, Chemotherapy, integumentary system, biology, business.industry, Merkel cell carcinoma, medicine.medical_treatment, food and beverages, medicine.disease, biology.organism_classification, Avelumab, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Javelin, 030220 oncology & carcinogenesis, Internal medicine, medicine, Skin cancer, business, medicine.drug
الوصف: 9507Background: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer with poor prognosis. Studies of second-line chemotherapy for metastatic MCC (mMCC) have reported median progression-fre...
تدمد: 1527-7755
0732-183X
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::1eeafa79347a5a669a8f07a8a894ebb6Test
https://doi.org/10.1200/jco.2018.36.15_suppl.9507Test
رقم الانضمام: edsair.doi...........1eeafa79347a5a669a8f07a8a894ebb6
قاعدة البيانات: OpenAIRE
الوصف
تدمد:15277755
0732183X